N. Xiao, Y.B. Yu / Journal of Fluorine Chemistry 131 (2010) 439–445
445
and purified by us as described in a previous publication [18].
Fmoc-norvaline (11) and Fmoc-norleucine (12) were purchased
from Aapptec. Other Fmoc-protected amino acids and rink amide
MBHA resin (0.65 mmol/g, 100–200 mesh) were purchased from
Novabiochem. All purchased amino acids were used without
further purification.
Eluents. EtOH was from Sigma–Aldrich (spectrophotometric
grade); ISP was from EMD (HPLC grade); TFE and HFIP were from
Oakwood Products (reagent grade). EtOH and ISP were used as
purchased. TFE and HFIP were distilled before usage.
hydrophobicity of peptides and amino acids [14]. The chro-
matographic conditions were: eluent A: 0.2% TFA in water; eluent
B: 0.2% TFA in CH3CN; gradient: 0.25% B/min, starting from 10% B;
flow rate: 0.3 mL/min; column temperature: 25 8C. Room temper-
ature was set at 20 8C. To avoid overcrowding the chromatogram,
injections were conducted in two batches: analytes 1–10 were co-
injected and analytes 9–12 were co-injected.
For separation analysis, the chromatographic conditions were:
eluent A: 0.1% TFA in water; eluent B: 0.1% TFA in EtOH, or TFE, or
ISP, or HFIP, or TFE/HFIP mixture (1:1); gradient: 1% B/min; flow
rate: 0.5 mL/min; column temperature: 5–60 8C. For column
temperatures below 20 8C, room temperature was set at 5 8C.
For column temperatures between 20 8C and 60 8C, room
temperature was set at 20 8C. Each pair of analytes was co-
injected. For detailed gradient conditions of each pair, see Table S1
of Supporting Information.
Columns. For separation studies, H-column, Zorbax Eclipse XDB-
C8 (4.6 mm ꢁ 150 mm, 5
m
m); F-column, FluoroFlash1 (4.6 mm ꢁ
150 mm, mm). For hydrophobicity analysis, Kromasil-C18
5
(2.1 mm ꢁ 150 mm, 5
(4.6 mm ꢁ 250 mm, 5
(4.6 mm ꢁ 250 mm, 5
m
m
m
m). For purity analysis, Zorbax XDB-C18
m). For chiral purity analysis, ChiraDex
m). For peptide purification, Zorbax C8
m).
preparative column (21.2 mm ꢁ 250 mm, 5
m
Instrumentation. HP1200 liquid chromatography system
Acknowledgements
(Agilent Technologies); JEOL ECX 9.4T NMR spectrometer
(
19F 367 MHz); LCQ Man-O.2.2 mass spectrometer.
This research was supported by NIH grant EB 004416 and the
Kimmel Foundation. YBY was a Kimmel scholar.
4.2. Peptide synthesis and purification
Peptides (3, 4, 7 and 8) were made using Fmoc solid-phase
chemistryonrinkamideMBHAresin. ExceptCys andtfT, allcoupling
reactions were conducted using the Liberty microwave peptide
synthesizer(5eq. Fmoc-AA-OH, 4.5eq.DIC, 5eq. HOBt, 5eq. DIPEAin
DMF, 75 8C, 200 s). Cys and tfT are prone to racemization and their
manual incorporation into peptides used the following conditions:
Cys, 5 eq. Fmoc-Cys(Trt)-OH, 4.5 eq. DIC, 5 eq. HOBt, no base, r.t., 3 h;
tfT, 3 eq. Fmoc-tfT(OtBu)-OH, 2.7 eq. DIC, 3.3 eq. HOBt, no base, 0.5
eq. CuCl2ꢂ2H2O in DMF/DCM (1/1), 0 8C, 16 h. CuCl2 was added to
reduce racemization [18]. Cyclic peptides (7 and 8) were made by
crosslinking the two cysteine residues in each peptide (intra-
molecular S-S bond) in 10 mM ammonium acetate aqueous solution
containing 17% DMSO (pH 7.0).
The peptides were purified using preparative reversed-phase
liquid chromatography (RPLC). The purity of each peptide was
verified using analytical reversed-phase and chiral liquid chroma-
tography. The molecular weight (MW) of each peptide was verified
using mass spectrometry (MS). The fluorinated octapeptide (8) was
further characterized by 19F NMR spectroscopy. For HPLC, MS and
NMR data on 3, 4, 7 and 8, see Supporting Information.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
References
[1] D. O’Hagan, D.B. Harper, J. Fluorine Chem. 100 (1999) 127–133.
[2] B.J. Stockman, J. Am. Chem. Soc. 130 (2008) 5870–5871.
[3] S. Purser, P.M. Moore, S. Swallow, V. Gouverneur, Chem. Soc. Rev. 37 (2008) 320–
330.
[4] K. Mu¨ ller, C. Faeh, F. Diederich, Science 317 (2007) 1881–1886.
[5] I.T. Horva´th, Green Chem. 10 (2008) 1024–1028.
[6] S.M. Brittain, S.B. Ficarro, A. Brock, E.C. Peters, Nat. Biotechnol. 4 (2005) 463–468.
[7] H.-J. Lehmler, Expert Opin. Drug Deliv. 4 (2007) 247–262.
[8] E.G. Schutt, D.H. Klein, R.M. Mattrey, J.G. Reiss, Angew. Chem. Int. Ed. 42 (2003)
3218–3235.
[9] D.P. Curran, Synth. Lett. 9 (2001) 1488–1496.
[10] D.P. Curran, Z. Lee, Green Chem. 3 (2001) G3–G7.
[11] A. Studer, S. Hadida, R. Ferritto, S.-Y. Kim, P. Jeger, P. Wipf, D.P. Curran, Science 275
(1997) 823–826.
[12] Z. Luo, Q. Zhang, Y. Oderaotoshi, D.P. Curran, Science 291 (2001) 1766–1769.
[13] M. Przybyciel, LC–GC 23 (2005) 554–565.
[14] W. Zhang, J. Fluorine Chem. 129 (2008) 910–919.
[15] K. Valko´, S. Espinosa, C.M. Du, E. Bosch, M. Rose´s, C. Bevan, M.H. Abraham, J.
Chromatogr. A 933 (2001) 73–81.
4.3. HPLC
[16] J.M. Kovacs, C.T. Mant, R.S. Hodges, Biopolymers (Pept. Sci.) 84 (2006) 283–297.
[17] F.T.T. Huque, K. Jones, R.A. Saunders, J.A. Platts, J. Fluorine Chem. 115 (2002)
119–128.
For hydrophobicity analysis, we followed the method devel-
oped by Hodges and co-workers for measuring the relative
[18] N. Xiao, Z.-X. Jiang, Y.B. Yu, Biopolymers (Pept. Sci.) 88 (2007) 781–796.